Clinical Efficacy of Niuhuang Chengqitang in Treatment of Acute Gastrointestinal Injury in Patients with Severe Traumatic Brain Injury and Its Effect on MTL， DAO， and NSE
10.13422/j.cnki.syfjx.20222492
- VernacularTitle:牛黄承气汤治疗重型颅脑损伤患者急性胃肠损伤的疗效及对血清MTL、DAO、NSE水平影响
- Author:
Jinbo HE
1
;
Zhengrong MAO
1
;
Shen AI
1
Author Information
1. First Affiliated Hospital of Henan University of Chinese Medicine， Zhengzhou 450000， China
- Publication Type:Journal Article
- Keywords:
severe traumatic brain injury;
acute gastrointestinal injury;
Niuhuang Chengqitang;
motilin;
diamine oxidase
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2022;28(24):131-137
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the clinical efficacy of Niuhuang Chengqitang in the treatment of acute gastrointestinal injury （AGI） in patients with severe traumatic brain injury （sTBI） and observe the effect on serum motilin （MTL）， diamine oxidase （DAO）， and neuron-specific enolase （NSE）. MethodBy the prospective randomized controlled trial （RCT） method， 86 sTBI inpatients with AGI were randomly divided into an observation group（43 cases）and a control group （43 cases）. All patients were given conventional western medicine treatment， including actively targeting the primary diseases and combined diseases， supply of enteral nutrition as soon as possible， and gastrointestinal agents， while those in the observation group received additional Niuhuang Chengqitang by nasal administration. The treatment course of both groups was 7 days. The clinical efficacy of the two groups was compared before treatment and 7 days after treatment. Gastrointestinal failure （GIF） score and intra-abdominal pressure （IAP） of the two groups were recorded， and serum MTL， DAO and NSE levels were detected before treatment， 3 days and 7 days after treatment. The Glasgow Coma Scale （GCS） score， duration of mechanical ventilation， length of ICU stay， and 28-day mortality were recorded. ResultDuring the treatment and observation， 4 cases fell off and 82 cases were finally enrolled， including 41 in the observation group and 41 in the control group. After treatment， the total effective rate in the observation group was 80.49%（33/41）， higher than 56.10%（23/41） in the control group （χ2=9.137，P<0.05）. GIF and IAP scores in the observation group were significantly improved after 3 and 7 days of treatment （P<0.01）， and the observation group was superior to the control group after 7 days of treatment （P<0.05）. The serum levels of MTL， DAO， and NSE in the two groups were improved after 3 and 7 days of treatment （P<0.05， P<0.01）. The levels of MTL and NSE in the observation group were better than those in the control group after 3 days of treatment （P<0.05， P<0.01）， and the levels of MTL， DAO， and NSE in the observation group were superior to those in the control group after 7 days of treatment （P<0.05， P<0.01）. The 28-day GCS score in the observation group was higher than that in the control group （P<0.01）， and the duration of mechanical ventilation and ICU stay in the observation group were significantly shorter than those in the control group （P<0.05）. There was no significant difference in 28-day mortality between the two groups. No adverse reactions related to Niuhuang Chengqitang occurred in the observation group. ConclusionNiuhuang Chengqitang can effectively improve the gastrointestinal function， regulate MTL， DAO， and NSE levels， shorten the ICU stay， and promote the recovery of sTBI patients with AGI.
